Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma

Allergology International

Norio Sato¹  Noriko Seko¹  Akira Hoshioka²  Komei Ito³  Motohiro Ebisawa⁴  Kazuyuki Kurihara⁵  Shigemi Yoshihara⁶  Hiroshi Odajima⁷  Sankei Nishima⁷  Kazuko Sugai⁸  Takahide Teramoto⁹  Toshio Katsunuma^1,10  Satoru Doi^1,11  Mitsuhiko Nambu^1,12  Koichi Yamaguchi^1,13  Akira Akasawa^1,14  Takao Fujisawa^1,15  Toshikazu Nagakura^1,16 

[1] Clinical Development, Novartis Pharma K.K., Tokyo, Japan;Department of Allergy and Rheumatology, Chiba Children's Hospital, Chiba, Japan;Department of Allergy, Aichi Children's Health and Medical Center, Obu, Japan;Department of Allergy, Clinical Research Center for Allergology and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan;Department of Allergy, Kanagawa Children's Medical Center, Yokohama, Japan;Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan;Department of Pediatrics, Fukuoka National Hospital, Fukuoka, Japan;Department of Pediatrics, Fukuyama Medical Center, Fukuyama, Japan;Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan;Department of Pediatrics, Jikei Daisan Hospital, Tokyo, Japan;Department of Pediatrics, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Japan;Department of Pediatrics, Tenri Hospital, Tenri, Japan;Department of Pediatrics, The Fraternity Memorial Hospital, Tokyo, Japan;Division of Allergy, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan;Institute for Clinical Research, Mie National Hospital, Tsu, Japan;Yoga Allergy Clinic, Tokyo, Japan;

关键词: Childhood asthma;    Efficacy;    Omalizumab;    Safety evaluation;    Total IgE;   

DOI  :  10.1016/j.alit.2016.06.004

来源: DOAJ

【 授权许可】

Unknown